Results 131 to 140 of about 65,232 (224)

Association Between Germline BRCA1/2 Gene Variants and Clinicopathological Features of Ovarian Cancer

International Journal of General Medicine
Yu Luo,1,2 Ru Pan,1,2 Hui Rao,2,3 Xing Chen,4 Haikun Yang1,2 1Department of Gynaecology, Meizhou People’s Hospital, Meizhou Academy of Medical Sciences, Meizhou, People’s Republic of China; 2Meizhou Municipal Engineering and Technology Research Center ...
Luo Y, Pan R, Rao H, Chen X, Yang H
doaj  

Occurrence of BRCA1 and BRCA2 mutation in pancreatic cancer patients

Сибирский онкологический журнал, 2016
BRCA1 and BRCA2 may contribute in pancreatic cancer (PC) risk, however the selection criteria for BRCA1 testing are poorly defined. The analysis of Russian founder mutation BRCA1 5382insC in 150 PC patients identified 2 carriers.
A. A. Kashintsev, G. A. Yanus, N. Yu. Kokhanenko, V. M. Moiseenko, M. D. Hanevich, L. D. Roman, A. G. Ievleva, A. P. Sokolenko, E. N. Suspitsin, A. I. Budovskiy, A. V. Togo, N. M. Volkov, R. V. Fadeev, M. S. Dinikin, A. K. Ivanova, K. G. Shostko, E. N. Imyanitov   +16 more
doaj  

Quantum‐Level Influences on Enzyme Reactions and Their Ripple Effects on Biological Phenomena

Advanced Physics Research, Volume 5, Issue 9, September 2026.
Because living organisms are ultimately composed of atoms and molecules, quantum‐mechanical effects are expected to contribute to biological phenomena. Quantum biology seeks to elucidate life processes from a quantum‐mechanical perspective. This review discusses how quantum‐level effects, including quantum tunneling, may propagate from enzymatic proton‐
Takeshi Yasuda
wiley   +1 more source

Nucleases and Their Inhibitors: Exploring Biological Roles, Industrial Applications, and Challenges in Heterologous Expression

Biotechnology Journal, Volume 21, Issue 9, September 2026.
Graphical Abstract and Lay Summary Intracellular nucleases, depicted as blue circles in a nucleosome, hydrolyze phosphodiester bonds, repair damaged DNA using DNA base excision repair (BER), mismatch repair (MMR), and homologous recombination (HR), and are involved in DNA replication.
Wian Vermeulen, Anton Du Preez van Staden, Leon M. T. Dicks   +2 more
wiley   +1 more source

Встречаемость мутаций в генах BRCA1 и BRCA2 у больных раком поджелудочной железы [PDF]

, 2016
BRCA1 and BRCA2 may contribute in pancreatic cancer (PC) risk, however the selection criteria for BRCA1 testing are poorly defined. The analysis of Russian founder mutation BRCA1 5382insC in 150 PC patients identified 2 carriers.
L. D. Roman, А. К. Иванова, A. A. Kashintsev, Е. Н. Суспицин, M. S. Dinikin, А. Г. Иевлева, Н. М. Волков, А. В. Того, М. С. Диникин, A. P. Sokolenko, Г. А. Янус, A. V. Togo, Н. Ю. Коханенко, A. I. Budovskiy, В. М. Моисеенко, V. M. Moiseenko, K. G. Shostko, E. N. Imyanitov, К. Г. Шостко, G. A. Yanus, E. N. Suspitsin, А. И. Будовский, A. G. Ievleva, R. V. Fadeev, М. Д. Ханевич, N. Yu. Kokhanenko, N. M. Volkov, А. П. Соколенко, Р. В. Фадеев, Е. Н. Имянитов, M. D. Hanevich, A. K. Ivanova, А. А. Кашинцев, Л. Д. Роман   +33 more
core  

PD‐L1 in Ovarian Cancer: Immune Evasion, Tumor‐Intrinsic Signaling, and Chemoresistance

Cancer Medicine, Volume 15, Issue 9, September 2026.
The “Dual Shield” model of PD‐L1 in ovarian cancer. On the outside, PD‐L1 engages PD‐1 to inactivate T cells and drive immune evasion (immune shield). Inside the tumor cell, PD‐L1 activates AKT–mTOR, enhances DNA repair, rewires metabolism, supports autophagy, and enforces stemness programs—collectively creating a chemoresistance shield.
Zhiyang Xu, Xiaohui Lv, Yunping Wang, Yanjie Ren   +3 more
wiley   +1 more source

Reactive Oxygen Species in Breast Cancer: From Redox Dysregulation to ROS‐Responsive Therapeutics

Cell Biochemistry and Function, Volume 44, Issue 9, September 2026.
ABSTRACT Breast cancer is the most frequently diagnosed malignancy among women worldwide, with 2.3 million new cases and approximately 670,000 deaths reported in 2022 alone. Despite advances in therapy, metastasis and acquired drug resistance remain major clinical challenges.
Marija Nikolovska, Radoslav Stojchevski, Aleksandar Eftimov, Mitko Mladenov, Dimiter Avtanski, Nikola Hadzi‐Petrushev   +5 more
wiley   +1 more source

Clinical Benefit of Pembrolizumab in Lynch Syndrome‐Associated Advanced Ovarian Cancer With Germline MSH6 Variant: A Case Report

Clinical Case Reports, Volume 14, Issue 9, September 2026.
ABSTRACT This case highlights the importance of genetic evaluation during treatment in young patients with advanced ovarian cancer. Lynch syndrome caused by a germline MSH6 pathogenic variant was diagnosed during first‐line maintenance therapy, and pembrolizumab achieved a durable response in recurrent disease.
Tomomi Yokozawa, Sayako Nakagawa, Yukio Suzuki, Aya Tokinaga‐Uchiyama, Katsuyuki Konnai, Hiroto Narimatsu, Yukihiko Hiroshima, Haruya Saji   +7 more
wiley   +1 more source

Breast and Contralateral Axillary Lymph Node Metastases After Ovarian Cancer Surgery: A Case Report

Clinical Case Reports, Volume 14, Issue 9, September 2026.
Histopathological and immunohistochemical findings supporting ovarian‐origin metastasis in the left axillary lymph node. Hematoxylin and eosin staining and immunohistochemical staining supported metastatic ovarian carcinoma rather than primary breast cancer.
Sihan Zhang, Zhiyuan Zhang, Jiaru Gao, Mengshen Wang, Minghui Zheng, Qiaonan Ye, Chenxi Yuan, Linjiao Jia, Wentao Li   +8 more
wiley   +1 more source

An In Vitro and In Vivo Assessment of the Anti‐Breast Cancer Activity of Erythrina excelsa Baker (Fabaceae) Bark Extracts

Cancer Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background Breast cancer remains a topic of interest due to its high mortality rate among Cameroonian women. The barks of Erythrina excelsa are traditionally used for medicinal purposes in the management of various conditions including cancer.
Jonas Walantini, Marius Trésor Kemegne Sipping, Merline Nguedia Ymele, Roland Nhouma Rebe, Joël Abel Gbaweng Yaya, Derek Tantoh Ndinteh, Dieudonné Njamen, Stéphane Zingue   +7 more
wiley   +1 more source